Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2017

View Archived Issues

Opiant reports phase I data on OPNT-002

JCR and Teijin partner on allogeneic regenerative medical product JTR-161 for stroke in Japan

Bioniz reports topline results from first-in-human study of BNZ-1

Emergent to acquire raxibacumab from GSK

Intranasal treatment with CYP-001 offers antiremodeling effects in mouse models of chronic asthma

FDA grants rare pediatric disease designation to Spark Therapeutics' Luxturna

Roche to end involvement in development of ORY-1001

Mutations in TMEM8C gene found to cause Carey-Fineman-Ziter syndrome

FDA grants orphan drug designation to gilteritinib for AML

FDA accepts for review Yonsa NDA for metastatic castration-resistant prostate cancer

FDA grants tentative approval for follow-on biologic basal insulin Lusduna Nexvue

Vitae Pharmaceuticals discloses menin/MLL interaction inhibitors

Shionogi & Co. patents MGAT2 inhibitors

Incyte treats first patient in phase III trial of itacitinib in acute graft-versus-host disease

U.S. phase II trial of T-817MA in mild to moderate Alzheimer's disease misses primary endpoints

ORIC Pharmaceuticals divulges glucocorticoid receptor antagonists

Merck & Co. discovers viral genome polyprotein inhibitors

Otsuka Pharmaceutical Factory identifies lipoprotein lipase activators

European Commission approves Veltassa to treat hyperkalemia

FDA accepts for review Aimovig BLA for migraine prevention

Kamada submits inhaled AAT phase III protocol to FDA for review

Novel F7 gene mutations identified in inherited FVII deficiency

NICE approves use of Kyprolis through English NHS

NICE recommends use of Cinqaero through English NHS

Phase II trial of Twin for acne achieved primary and secondary efficacy endpoints

BiondVax reports phase IIb data on universal flu vaccine candidate M-001

CIRM grant to support Brainstorm's planned phase III study of NurOwn for ALS

European Commission approves Dompe's cenegermin eye drops for neurotrophic keratitis

BAY-386, a novel PAR1 receptor inhibitor for arterial thrombosis

Ironwood reports topline phase IIb data on IW-3718 in uncontrolled GERD

Auris Medical completes acquisition of intranasal betahistine assets from Otifex Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...